ライフサイエンスコーパス: meningococcal

1 s yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months,

2 A new meningococcal A conjugate vaccine (PsA-TT) is about to b

3 A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) w

4 cation (Africa and globally), development of meningococcal A disease vaccination campaigns in Africa,

5 programme, alongside an emergency adolescent meningococcal ACWY (MenACWY) programme to control a nati

6 owed reduced antibiofilm activity, increased meningococcal adhesion, and increased invasion of cells,

7 Total meningococcal and genotypically serogroup B carriage pre

8 lution of the Neisseria, the epidemiology of meningococcal and gonococcal disease, and mechanisms of

9 atically in the pharynx, possibly modulating meningococcal and gonococcal infections.

10 -KO), and/or a control rFHbp vaccine against meningococcal and gonococcal strains.

11 The most prevalent meningococcal and H. influenzae strains were serogroup W

12 ional validation datasets from patients with meningococcal and inflammatory diseases, bacterial infec

13 nduces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccina

14 The Meningococcal Antigen Typing System (MATS) was used to e

15 factor H-binding proteins representative of meningococcal B epidemiologic diversity; an hSBA titer o

16 cited bactericidal responses against diverse meningococcal B strains after doses 2 and 3 and was asso

17 We used 14 meningococcal B test strains that expressed vaccine-hete

18 effectiveness of the outer membrane vesicle meningococcal B vaccine (MeNZB) against gonorrhoea in yo

19 MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding prote

20 Recently, the outer membrane vesicle (OMV) meningococcal B vaccine, MeNZB, was reported to be assoc

21 survey, 20%-24% of participants carried any meningococcal bacteria and 4% carried serogroup B by rt-

22 13, CRM-conjugated) at 2-4 months and 1 or 2 meningococcal C vaccine (MCC-CRM- or MCC-TT) doses at 3-

23 Here 211 meningococcal carriage and >1,400 disease isolates were

24 MenB-4C do not have a large, rapid impact on meningococcal carriage and are unlikely to provide herd

25 cal (MenB) vaccines MenB-FHbp and MenB-4C on meningococcal carriage and herd protection.

26 me composition showed weak associations with meningococcal carriage and risk factors for carriage.

27 Although risk factors for meningococcal carriage do not strongly impact most bacte

28 We therefore assessed meningococcal carriage following a MenB vaccination camp

29 Study of meningococcal carriage is essential to understanding the

30 uitable approach for the characterization of meningococcal carriage isolates.

31 he serogrouping and capsular genogrouping of meningococcal carriage isolates.

32 suggesting MenB-FHbp does not rapidly reduce meningococcal carriage or prevent serogroup B carriage a

33 between bacterial community composition and meningococcal carriage or risk factors for carriage, inc

34 vious study of Georgia high school students, meningococcal carriage prevalence was 7%.

35 Meningococcal carriage rates in US high school students

36 Meningococcal carriage was highest in 24- to 39-year-old

37 The inhibition of meningococcal carriage was only observed in carriers of

38 We investigated MenB-FHbp impact on meningococcal carriage.

39 CI, 1.1-1.5) were associated with increased meningococcal carriage.

40 ing orogenital contact with an oropharyngeal meningococcal carrier.

41 Here, we report structures of meningococcal Cas9 homologs in complex with sgRNA, dsDNA

42 n age and clinical manifestation and less on meningococcal CC or serogroup.

43 Meningococcal CCs were assessed by multilocus sequence t

44 been attributed to a unique non-encapsulated meningococcal clade (the US Nm urethritis clade, US_NmUC

45 orA PCR-sequencing assay were used to detect meningococcal colonisation and a carriage rate of 32.6%

46 o receive either a TCV or a capsular group A meningococcal conjugate vaccine (MenA) as a control.

47 the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control.

48 ert consultations recommended that a group A meningococcal conjugate vaccine be developed and introdu

49 An effective low-cost multivalent meningococcal conjugate vaccine could help further contr

50 of HIV-infected persons with a quadrivalent meningococcal conjugate vaccine in accordance with Advis

51 A new group A meningococcal conjugate vaccine was developed to elimina

52 he anticipated introduction of a multivalent meningococcal conjugate vaccine within Africa's meningit

53 in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), di

54 that included the introduction of a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in

55 The recent introduction of a new group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in

56 In 2012, a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), wa

57 A group A meningococcal conjugate vaccine, PsA-TT, was licensed in

58 Meningococcal conjugate vaccines against serogroups A, C

59 Affordable multivalent meningococcal conjugate vaccines are being developed to

60 may continue to occur; effective multivalent meningococcal conjugate vaccines could improve meningoco

61 e World Health Organization (WHO) to develop meningococcal conjugate vaccines for sub-Saharan Africa.

62 ation registry data and serogroup B invasive meningococcal disease (B-IMD) cases notified to public h

63 Invasive meningococcal disease (IMD) caused by Neisseria meningit

64 Invasive meningococcal disease (IMD) due to serogroup Y Neisseria

65 Invasive meningococcal disease (IMD) incidence increased in Quebe

66 Invasive meningococcal disease (IMD) is a worldwide health issue

67 Invasive meningococcal disease (IMD) is endemic to South Africa,

68 In contrast to invasive meningococcal disease (IMD) isolates, which can be readi

69 An increase in invasive meningococcal disease (IMD) serogroup W (IMD-W) cases ca

70 d for the prevention of invasive serogroup B meningococcal disease (IMD) since their licensure in 201

71 n polymorphisms are associated with invasive meningococcal disease (IMD), but the contributions of ra

72 (TPD) are susceptible to recurrent invasive meningococcal disease (IMD).

73 t can even cause large epidemics of invasive meningococcal disease (IMD).

74 tely capture other presentations of invasive meningococcal disease (IMD).

75 characterized the burden of non-serogroup A meningococcal disease (including the emergence of a new

76 Meningococcal disease (MD) remains an important infectio

77 ertaken in separate studies of children with meningococcal disease (n = 24) and inflammatory diseases

78 across North America and Europe of invasive meningococcal disease among men who have sex with men (M

79 Several clusters of serogroup C meningococcal disease among men who have sex with men (M

80 The epidemiology and risk of meningococcal disease among MSM is not well described.

81 Annualized incidence of meningococcal disease among MSM was 0.56 cases per 10000

82 present a step forward in the battle against meningococcal disease and will help reassure that the va

83 Laboratory-confirmed cases of meningococcal disease are followed up with PHE local hea

84 All meningococcal disease cases among men aged 18-64 years r

85 Characteristics of meningococcal disease cases among MSM and men not known

86 Isolates from meningococcal disease cases among MSM were characterized

87 alidated with 12 CSF specimens from invasive meningococcal disease cases and 12 urine specimens from

88 ed cases account for approximately 5% of all meningococcal disease cases in the United States.

89 A retrospective review of all meningococcal disease cases reported from 1 January 2009

90 Serogroup B meningococcal disease caused 7 US university outbreaks d

91 eins licensed for the prevention of invasive meningococcal disease caused by meningococcal serogroup

92 in 33.9% of vaccinees, although no cases of meningococcal disease caused by N. meningitidis B were r

93 nd to compare this protection to an invasive meningococcal disease challenge model.

94 likely among children who developed invasive meningococcal disease compared with matched controls wit

95 We report the recent emergence of invasive meningococcal disease due to serogroup E in Queensland,

96 these regions and construct a global view of meningococcal disease epidemiology.

97 2009, increases in the incidence of invasive meningococcal disease have occurred in the United Kingdo

98 trols and group B and all serogroup invasive meningococcal disease in cases compared with controls wh

99 s enhanced national surveillance of invasive meningococcal disease in England and Wales.

100 m enhanced national surveillance of invasive meningococcal disease in England, we evaluated the effec

101 condary outcomes were all serogroup invasive meningococcal disease in fully vaccinated cases compared

102 The primary outcome was group B invasive meningococcal disease in fully vaccinated cases compared

103 explanation for the large number of cases of meningococcal disease in immunized patients being treate

104 nation may provide better protection against meningococcal disease in patients treated with an AP-spe

105 lp explain the historically low incidence of meningococcal disease in the United States.

106 ary to monitor the molecular epidemiology of meningococcal disease in these regions and construct a g

107 a spp. following the eighth case of invasive meningococcal disease in young children (5 to 46 months)

108 y vaccine in use to prevent group B invasive meningococcal disease in young children, but no matched

109 Meningococcal disease incidence in the United States is

110 Although the incidence of meningococcal disease is low in the United States, outbr

111 Invasive meningococcal disease is mainly caused by Neisseria meni

112 Following a meningococcal disease outbreak at a U.S. college, we pro

113 aign in response to a university serogroup B meningococcal disease outbreak in 2015.

114 r Disease Control and Prevention to identify meningococcal disease outbreaks.

115 ases and may have important contribution for meningococcal disease pathology.

116 ithin Africa's meningitis belt, will enhance meningococcal disease prevention across the belt.

117 ningococcal conjugate vaccines could improve meningococcal disease prevention within meningitis belt

118 e identified familial cases of IMD in the UK meningococcal disease study and the European Union Life-

119 Public Health England conducts meningococcal disease surveillance in England.

120 We applied this method to meningococcal disease susceptibility, using the DNA bind

121 s11913168, showing signs of association with meningococcal disease susceptibility.

122 nd (PHE) undertakes enhanced surveillance of meningococcal disease through a combination of clinical,

123 Portugal with laboratory-confirmed invasive meningococcal disease were included.

124 Seventy-four cases of meningococcal disease were reported among MSM and 453 am

125 16 and September 2017, four cases of group B meningococcal disease were reported among sixth-form col

126 From 2009 to 2013, a total of 3686 cases of meningococcal disease were reported in the United States

127 , 0.08-0.44]) and for all serogroup invasive meningococcal disease, 11 of 98 cases (11.2%) and 61 of

128 For all serogroup invasive meningococcal disease, 6 of 85 cases (7.1%) and 39 of 17

129 Of 117 patients with invasive meningococcal disease, 98 were eligible for inclusion an

130 MSM are at increased risk for meningococcal disease, although the incidence of disease

131 thogen responsible for outbreaks of invasive meningococcal disease, including among men who have sex

132 l pack of investigations and were tested for meningococcal disease, of whom 148 consented and were en

133 patients are at >1000-fold increased risk of meningococcal disease, vaccination is recommended; wheth

134 ization by commensal Neisseria lactamica and meningococcal disease, we investigated whether controlle

135 a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisat

136 invaluable for studying the epidemiology of meningococcal disease.

137 stain individual protection against invasive meningococcal disease.

138 cine licensed to protect against serogroup B meningococcal disease.

139 er of the bacteria, and can lead to invasive meningococcal disease.

140 l epithelial cells is a new genetic cause of meningococcal disease.

141 he most effective strategy for prevention of meningococcal disease.

142 licensed to protect against invasive group B meningococcal disease.

143 ogroup Y (MenY) strains are a major cause of meningococcal disease.

144 MenW was responsible for 15% of all invasive meningococcal disease.

145 arry tspB genes are associated with invasive meningococcal disease.

146 er mucosal infections, and cases of invasive meningococcal disease.

147 pared with matched controls without invasive meningococcal disease.

148 ation, we identify and describe outbreaks of meningococcal disease.

149 le for inclusion and 82 had group B invasive meningococcal disease; 69 were old enough to have been f

150 e very infrequently associated with invasive meningococcal disease; however, those belonging to the '

151 ns have been licensed; both vaccines contain meningococcal factor H binding protein (fHbp).

152 Cocrystal structure of meningococcal factor H binding protein variant 3 reveals

153 p binds CFH with affinity similar to that of meningococcal fHbp and promotes survival of N. cinerea i

154 at the antigenic gene is prevalent among non-meningococcal flora, most likely Neisseria commensals.

155 identified as being induced and repressed by meningococcal Fur.

156 yesian method on 103 Italian and 208 foreign meningococcal genomes.

157 meningitidis are possible across a range of meningococcal genotypes.

158 ration for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for th

159 A meningococcal group A conjugate vaccine, PsA-TT (also kn

160 A meningococcal group A conjugate vaccine, PsA-TT (MenAfri

161 (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or

162 Subjects received either PsA-TT; meningococcal group A, C, W, Y polysaccharide vaccine (P

163 he effect of vaccination on the incidence of meningococcal group B disease during the first 3 years o

164 iated with continued positive effect against meningococcal group B disease in children in England, an

165 r 2015 through August 2018, the incidence of meningococcal group B disease in England (average annual

166 r the 3-year period, there were 169 cases of meningococcal group B disease in the vaccine-eligible co

167 The adjusted vaccine effectiveness against meningococcal group B disease was 52.7% (95% CI, -33.5 t

168 d to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 i

169 aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15,

170 In 2014-15, 165 of 251 (66%; 95% CI 52-80) meningococcal group B isolates were estimated by MATS to

171 INTERPRETATION: In 2014-15, two-thirds of meningococcal group B isolates were predicted to be cove

172 United Kingdom introduced the multicomponent meningococcal group B vaccine (4CMenB, Bexsero) into its

173 The meningococcal group B vaccine 4CMenB is a new, recombina

174 4CMenB is a protein-based meningococcal group B vaccine but the vaccine antigens m

175 nce data suggest that outer membrane vesicle meningococcal group B vaccines affect the incidence of g

176 No deaths or cases of meningococcal infection occurred during the study.

177 within OMVs in providing protection against meningococcal infection.

178 n meningitis belt has eliminated serogroup A meningococcal infections for >300 million Africans.

179 ve critical impact on the pathophysiology of meningococcal infections.

180 s the way for a novel therapeutic option for meningococcal infections.

181 pective on regulatory mechanisms involved in meningococcal interaction with epithelial cells, and sug

182 We determined that nonencapsulated meningococcal isolates from an ongoing Nm urethritis out

183 Invasive serogroup B meningococcal isolates from cases in England, Wales, and

184 tionality between galE1 and galE2 alleles in meningococcal isolates was retained for all serogroups e

185 knockout mutants prepared from two sensitive meningococcal isolates.

186 MP) LL-37 with the meningococcal surface and meningococcal killing.

187 e aimed to assess the diagnostic accuracy of meningococcal LAMP as a near-patient test in the emergen

188 At least 20 meningococcal lineages were identified, three of which (

189 Furthermore, co-expression of meningococcal lpxH and lpxA resulted in viable cells tha

190 Expression of meningococcal LpxH in B. pertussis indeed resulted in ne

191 A group A meningococcal (MenA) conjugate vaccine has progressively

192 e vaccines have been used to control group A meningococcal (MenA) epidemics with minimal success.

193 The capsular group B meningococcal (MenB) four component vaccine (4CMenB) has

194 ntry to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a pu

195 bp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to control a coll

196 data exist on the impact of the serogroup B meningococcal (MenB) vaccines MenB-FHbp and MenB-4C on m

197 is a target of two licensed group B-directed meningococcal (MenB) vaccines.

198 fatality rate was 6-fold higher than that of meningococcal meningitis (28% vs 5%).

199 After the re-emergence of serogroup C meningococcal meningitis (MM) in Nigeria and Niger, we a

200 o- or nasopharynx and the causative agent of meningococcal meningitis and meningococcemia, is capable

201 After the major group A meningococcal meningitis epidemics in 1996-1997 (250,000

202 conjugate vaccine could help further control meningococcal meningitis in the region.

203 Meningococcal meningitis incidence was highest in the re

204 These associations did not seem to apply to meningococcal meningitis or viral meningitis.

205 ACV has reduced serogroup A outbreaks, large meningococcal meningitis outbreaks due to other serogrou

206 Meningococcal meningitis remains a significant public he

207 Meningococcal meningitis remains a substantial cause of

208 nd a substantial effect on confirmed group A meningococcal meningitis.

209 cohort studies comprising 373 patients with meningococcal meningitis.

210 tions, such as outbreaks of yellow fever and meningococcal meningitis.

211 olates were surveyed for the distribution of meningococcal mod alleles.

212 provide a perspective on the use of WGS for meningococcal molecular surveillance and outbreak invest

213 iagnosed between 20 and 55 years of age with meningococcal (n = 451), pneumococcal (n = 553), or vira

214 The structural integrity of meningococcal native, micro-fluidized and activated caps

215 In Burkina Faso, serogroup A meningococcal (NmA) conjugate vaccine (PsA-TT, MenAfriVa

216 While a meningococcal NMB0419 mutant did not have altered epithe

217 A meningococcal NOMV vaccine elicits SBA against gonococci

218 ed or receiving disability pension in former meningococcal or viral meningitis patients versus member

219 Against 2 meningococcal outbreak strains with mismatched PorA and

220 Meningococcal outer membrane vesicle (OMV) vaccines are

221 ren presenting at the hospital underwent the meningococcal pack of investigations and were tested for

222 ID 896), was highly expressed by an emerging meningococcal pathotype, the nonencapsulated urethritis

223 mophilus influenzae type b (Hib) and group C meningococcal polysaccharides, as well as tetanus toxoid

224 reflect genetic diversity in the underlying meningococcal population rather than novel adaptation to

225 e by whole-genome sequencing and compare the meningococcal population structure of Swedish invasive s

226 The meningococcal population structures were similar in the

227 Binding of FH increases meningococcal resistance to complement-mediated killing.

228 nts, meningococcal serogroup C vaccine in 2, meningococcal serogroup A and Haemophilus influenzae typ

229 A novel meningococcal serogroup A conjugate vaccine (MACV [MenAf

230 After successful meningococcal serogroup A conjugate vaccine (MACV) campa

231 the meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has b

232 With the rollout of a novel meningococcal serogroup A conjugate vaccine (MACV) in th

233 In 2010-2017, meningococcal serogroup A conjugate vaccine (MACV) was i

234 Meningococcal serogroup A conjugate vaccine (MACV) was i

235 onitor meningitis epidemiology and impact of meningococcal serogroup A conjugate vaccine (MACV).

236 belt implemented vaccination campaigns with meningococcal serogroup A conjugate vaccine (MACV).

237 other meningitis belt countries introduced a meningococcal serogroup A conjugate vaccine (MACV).

238 n Burkina Faso following the introduction of meningococcal serogroup A conjugate vaccine in 2010.

239 Since the progressive introduction of the meningococcal serogroup A conjugate vaccine within Afric

240 The introduction and rollout of a meningococcal serogroup A conjugate vaccine, MenAfriVac,

241 in a 1:1 ratio to receive either Vi-TCV or a meningococcal serogroup A conjugate vaccine.

242 mplements the MenAfriVac vaccination against meningococcal serogroup A to prevent meningitis outbreak

243 In December 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used befo

244 blood from 12 healthy adults vaccinated with meningococcal serogroup B and serogroup A, C, W, Y vacci

245 accine approved in the USA for prevention of meningococcal serogroup B disease in 10-25-year-olds.

246 ased vaccines, Bexsero and Trumenba, against meningococcal serogroup B strains have been licensed; bo

247 of invasive meningococcal disease caused by meningococcal serogroup B strains.

248 using human complement (hSBA) by use of four meningococcal serogroup B test strains expressing vaccin

249 e than 50% of participants for three of four meningococcal serogroup B test strains representative of

250 e than 50% of participants for three of four meningococcal serogroup B test strains representative of

251 The multicomponent meningococcal serogroup B vaccine (4CMenB) is an outer m

252 MenB-4C is a recently licensed meningococcal serogroup B vaccine.

253 o assess possible herd immunity effects with meningococcal serogroup B vaccines and the need for a bo

254 In contrast, 2 licensed meningococcal serogroup B vaccines, including one contai

255 milarities of meningococcal serogroup W with meningococcal serogroup C emergence, the rapid expansion

256 3-valent pneumococcal vaccine in 9 patients, meningococcal serogroup C vaccine in 2, meningococcal se

257 tudy, we used national surveillance data for meningococcal serogroup W and serogroup C disease in the

258 Cases due to meningococcal serogroup W cc11 (MenW:cc11) emerged in 20

259 Since 2009, the incidence of meningococcal serogroup W disease has increased rapidly

260 In the Netherlands, the incidence of meningococcal serogroup W disease increased substantiall

261 ands has had an increase in the incidence of meningococcal serogroup W disease.

262 TATION: Given the historical similarities of meningococcal serogroup W with meningococcal serogroup C

263 olysaccharide vaccines are available against meningococcal serogroups A, C, W, and Y.

264 d remain vigilant against threats from other meningococcal serogroups and other pathogens.

265 ntial to provide some protection against all meningococcal serogroups.

266 amount of protein expressed by the different meningococcal strains and this could be predicted from t

267 Recently, meningococcal strains associated with outbreaks of ureth

268 cted the dispersal patterns of hypervirulent meningococcal strains of serogroup C:cc11 by phylogenomi

269 mortality after lethal invasive doses of all meningococcal strains tested.

270 Unusual meningococcal strains with low level of virulence simila

271 e antimicrobial peptide (AMP) LL-37 with the meningococcal surface and meningococcal killing.

272 meningitidis capsule, which is critical for meningococcal surveillance and outbreak investigations.

273 -related schedules for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid

274 sis of the selective receptor recognition by meningococcal Tfp and thereby, identify a potential anti

275 We found that meningococcal Tfp specifically recognize a triantennary

276 B, and exbD, based on a known phenotype of a meningococcal tonB mutant.

277 In conclusion, meningococcal TPS system 2 and/or 3 is associated with d

278 ium will allow for a better understanding of meningococcal transcriptome organization and riboregulat

279 y demonstrates how housing density can drive meningococcal transmission and carriage, which likely fa

280 al disease cases and 12 urine specimens from meningococcal urethritis cases.

281 sepsis worldwide and an occasional cause of meningococcal urethritis.

282 Rare sporadic cases of meningococcal urogenital and anorectal infections, inclu

283 in SLSJ, using the 4-component protein-based meningococcal vaccine (MenB-4C).

284 d influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085).

285 immunological cross-reactivity of different meningococcal vaccine antigen variants.

286 ity to N. gonorrhoeae of serum raised to the meningococcal vaccine Bexsero, which contains the MeNZB

287 No patients reported previous meningococcal vaccine exposure.

288 cine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0.02).

289 eported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the tri

290 ere first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent ina

291 93 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6

292 was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inac

293 i-TT), Vi-polysaccharide (Vi-PS), or control meningococcal vaccine with a computer-generated randomis

294 The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis be

295 nactivated influenza vaccine or quadrivalent meningococcal vaccine.

296 Combined with evidence that two meningococcal vaccines are likely partially protective a

297 Meningococcal vaccines that target both NspA and FHbp ar

298 f tetanus/diphtheria/acellular pertussis and meningococcal vaccines, respectively, was delayed by 1 w

299 lopment not only for gonorrhoea but also for meningococcal vaccines.

300 mponents and different levels of coverage of meningococcal variants.